Compare CRNX & HGV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | HGV |
|---|---|---|
| Founded | 2008 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.2B |
| IPO Year | 2018 | 2017 |
| Metric | CRNX | HGV |
|---|---|---|
| Price | $83.73 | $48.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 8 |
| Target Price | ★ $76.75 | $52.13 |
| AVG Volume (30 Days) | ★ 6.8M | 1.0M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.78 |
| EPS | N/A | ★ 0.79 |
| Revenue | $1,039,000.00 | ★ $5,047,000,000.00 |
| Revenue This Year | $720.10 | $25.30 |
| Revenue Next Year | $184.67 | $1.98 |
| P/E Ratio | ★ N/A | $61.42 |
| Revenue Growth | N/A | ★ 1.33 |
| 52 Week Low | $25.83 | $36.79 |
| 52 Week High | $84.00 | $55.40 |
| Indicator | CRNX | HGV |
|---|---|---|
| Relative Strength Index (RSI) | 92.07 | 44.13 |
| Support Level | $33.50 | $48.03 |
| Resistance Level | N/A | $49.77 |
| Average True Range (ATR) | 0.18 | 1.54 |
| MACD | -0.10 | -0.30 |
| Stochastic Oscillator | 53.51 | 24.94 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts and timeshare plans under the Hilton Grand Vacations brand. The company operates in two segments: Real estate sales and financing, and Resort operations and club management. The Real estate sales and financing segment generates revenue from VOI sales and consumer financing, including interest income from loans to members. The Resort operations and club management segment generates revenue from resort management services, club membership fees, and rental of available inventory. The majority of the company's revenue is earned through the Real estate sales and financing segment.